In patients with locoregional recurrence of breast cancer, the effects of chemotherapy are varied, depending on whether they have hormone receptor positive or hormone receptor negative disease.
"If chemotherapy is going to have an impact on patient outcome following a locoregional recurrence, it's going to be in patients with hormone receptor negative disease," said William Gradishar, MD, professor of medicine, Northwestern University, Evanston, IL.
He added that the data are limited, however, in these patients.
In hormone receptor positive disease, chemotherapy has no impact.
Therefore, added Dr. Gradishar, "We have to individualize and be highly selective about where we use chemotherapy.